Multi-Site Validation of a Newly FDA-Cleared Automated Methotrexate Immunoassay for Therapeutic Drug Monitoring
The Journal of Applied Laboratory Medicine · 2026
DOI: 10.1093/jalm/jfaf189 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, 2026. Verfasst von Shaimaa Maher und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United State…. Hauptthemen laut MEDLINE: Methotrexate, Drug Monitoring, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Methotrexate (MTX), a synthetic antimetabolite and folic acid antagonist, has become a cornerstone in the management of malignant diseases. However, MTX toxicity can be severe and potentially life-threatening, especially with high-dose regimens used in oncology. Given its narrow therapeutic index, precise monitoring of MTX levels is critical to optimize efficacy while minimizing toxicity.
Methods
We validated the performance of the Roche ONLINE therapeutic drug monitoring (TDM) Methotrexate Assay on Cobas c502 and Cobas pro c503 platforms across 2 clinical sites, focusing on key analytical parameters such as linearity, accuracy, precision, dilution, carryover, and method comparison.
Results
The assay was linear across the analytical measurement interval (AMI) of 0.04–1.2 µmol/L. No significant carryover was observed (i.e., <5% bias). Automatic and manual dilutions demonstrated <10% bias, and the coefficients of variation (CVs) for precision and percentage bias for accuracy were <10%. A method comparison using 40 patient samples showed a strong correlation between the Roche and ARK MTX assays, with a Deming regression slope of 0.9634, an intercept of −0.0095, and Pearson correlation coefficient (r) = 0.9935, with a mean percentage difference (%Bias) of −12. Comparison with LC-MS/MS demonstrated high agreement for both assays. The ARK assay yielded a slope of 0.8873, an intercept of 0.0145, r = 0.9978, and %Bias of −6, while the Roche assay yielded a slope of 0.8541, an intercept of 0.0047, r = 0.9919, and %Bias of −18.
Conclusions
The Roche ONLINE TDM MTX assay is a robust and clinically adequate method for methotrexate quantification and therapeutic drug monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
ORCID-Profile: Lu Song
Zitieren
APA
Maher, S., Buggs, V., Ravelo, P., Song, L., & Metushi, I. G. (2026). Multi-Site Validation of a Newly FDA-Cleared Automated Methotrexate Immunoassay for Therapeutic Drug Monitoring. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfaf189
Vancouver
Maher S, Buggs V, Ravelo P, Song L, Metushi IG. Multi-Site Validation of a Newly FDA-Cleared Automated Methotrexate Immunoassay for Therapeutic Drug Monitoring. The Journal of Applied Laboratory Medicine. 2026. doi:10.1093/jalm/jfaf189
BibTeX
@article{Maher2026,
author = {Maher, Shaimaa and Buggs, Vincent and Ravelo, Patrick and Song, Lu and Metushi, Imir G},
title = {Multi-Site Validation of a Newly FDA-Cleared Automated Methotrexate Immunoassay for Therapeutic Drug Monitoring},
journal = {The Journal of Applied Laboratory Medicine},
year = {2026},
doi = {10.1093/jalm/jfaf189}
}
EUVIMED